CD274 and breast carcinoma: Biomarker studies have shown that PD-1+ TILs are associated with poor prognosis in HER2 positive breast cancer [77,78] and preliminary data also suggest a relationship between PD-L1 expression on tumor cells and objective response to anti PD-1 therapy [79].